Announcements
- Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
- Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
- Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
- Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
As of last trade Crinetics Pharmaceuticals Inc (6Z4:FRA) traded at 46.60, -2.10% below its 52-week high of 47.60, set on May 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 46.60 |
---|---|
High | 46.60 |
Low | 46.60 |
Bid | 46.60 |
Offer | 46.80 |
Previous close | 45.40 |
Average volume | 2.44 |
---|---|
Shares outstanding | 78.86m |
Free float | 75.72m |
P/E (TTM) | -- |
Market cap | 3.99bn USD |
EPS (TTM) | -3.77 USD |
Data delayed at least 15 minutes, as of May 23 2024 07:03 BST.
More ▼